Potent TRPM8 antagonist (IC50
values are 5.3 and 8.3 nM for rat and human channels respectively). Exhibits >350-fold selectivity for TRPM8 over TRPV4, TRPV1 and TRPA1. Reduces HSC3 and HSC4 oral squamous carcinoma cell migration and invasion in vitro
. Also attenuates icilin
-induced wet dog shakes in rats. Orally active.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Blockade of TRPM8 activity reduces the invasion potential of oral squamous carcinoma cell lines.
Okamoto et al.
Identification of a novel 2-pyridyl-benzensulfonamide derivative, RQ-00203078, as a selective and orally active TRPM8 antagonist.
Ohmi et al.